Literature DB >> 17329566

Chemokine regulation of atherosclerosis.

Jana Barlic1, Philip M Murphy.   

Abstract

Oxidative stress and inflammation are accepted as major factors in the pathogenesis of atherosclerosis, but how they interact to produce a plaque has not been delineated clearly. Recent data suggest that oxidized lipids may act in part by regulating production of chemokines and chemokine receptors, which in turn, may direct monocytes and other blood leukocytes to the vessel wall, where they may interact with endothelial cells and smooth muscle cells. The receptors may act at the level of recruitment, retention, and egress, not only through classic, chemotactic mechanisms but also through direct, intercellular adhesion. The results suggest a coordinated mechanism for inflammatory cell accumulation in plaque and identify novel targets, such as CCR2 and CX3CR1, for potential drug development in coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329566     DOI: 10.1189/jlb.1206761

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  37 in total

Review 1.  Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.

Authors:  Stavros Apostolakis; Virginia Amanatidou; Demetrios A Spandidos
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

2.  Transcriptional regulation of beta2-microglobulin demonstrated via a novel genomic and proteomic analysis of percutaneously collected peripheral atheroma.

Authors:  Brian L Stauffer; Erich J Kushner; Ted Wulfman; Thomas Zeller; Rebecca Sobus; Christian M Westby
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

3.  Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion.

Authors:  Jana Barlic; Wenjia Zhu; Philip M Murphy
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

Review 4.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

5.  RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role.

Authors:  Debjani Tripathy; Lakshmi Thirumangalakudi; Paula Grammas
Journal:  Neurobiol Aging       Date:  2008-04-28       Impact factor: 4.673

Review 6.  Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease.

Authors:  Suzanne E Hickman; Joseph El Khoury
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 7.  Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease.

Authors:  Stavros Apostolakis; Georgios K Chalikias; Dimitrios N Tziakas; Stavros Konstantinides
Journal:  Acta Pharmacol Sin       Date:  2011-03-28       Impact factor: 6.150

Review 8.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

9.  Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist.

Authors:  Timothy Wyant; Alan Lackey; Marie Green
Journal:  J Transl Med       Date:  2008-12-01       Impact factor: 5.531

10.  Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat.

Authors:  Grégory Lacraz; Marie-Hélène Giroix; Nadim Kassis; Josiane Coulaud; Anne Galinier; Christophe Noll; Mélanie Cornut; Fabien Schmidlin; Jean-Louis Paul; Nathalie Janel; Jean-Claude Irminger; Micheline Kergoat; Bernard Portha; Marc Y Donath; Jan A Ehses; Françoise Homo-Delarche
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.